Edesa Biotech's Paridiprubart Shows 32% Mortality Reduction in Exploratory AKI Data
EDSA has more than doubled off its 52-week low of $0.72 on light trading volume (0.1× avg).
Summary
Edesa Biotech announced positive exploratory clinical data for its drug paridiprubart in patients with acute kidney injury (AKI). The data showed a 32% relative reduction in 28-day mortality and a 23% relative reduction in major adverse kidney events (MAKE30) in a combined cohort of 101 patients. This news, also disclosed in an 8-K today, provides a significant positive development for the clinical-stage biotech, which recently reported a wider net loss and a going concern warning. While the findings are exploratory and require confirmatory studies, the magnitude of the observed benefit in a high-mortality condition is highly material.
At the time of this announcement, EDSA was trading at $7.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $63M. The 52-week trading range was $0.72 to $20.32. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.